Merck & Co Inc

NYSE: MRK
$96.31
-$2.05 (-2.1%)
Closing Price on November 15, 2024

MRK Articles

The March 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased, with two major movers in the group.
According to Credit Suisse, Pfizer investors might be getting to make up some of that relative underperformance of late.
The March 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased, with two major movers in the group.
Stock buybacks have come under more scrutiny by the public and politicians in recent years, but companies still aggressively are buying back shares of their own stock.
During times of uncertainty and fear, many investors have to look for a place to hide when they know that they have to keep having income from investments to supplement their income, retirement or...
The February 28 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased, with one major exception.
These five outstanding ideas from Merrill Lynch are decidedly more conservative. Given their strong and consistent dividends, they offer investors excellent total return potential and a safer way to...
The February 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
The top analyst upgrades, downgrades and initiations seen on Friday included Biogen, Broadcom, Citigroup, Equifax, Fitbit, Intel, Kraft Heinz, Merck, Roku, Under Armour, United Technologies and...
Immune Design shares absolutely exploded on Thursday after Merck announced that it would be acquiring the firm at what some might call a ridiculous premium
The top analyst upgrades, downgrades and initiations seen on Wednesday included CenturyLink, Deere, Ecolab, E*Trade, Merck, Southwest Airlines, S&P, Transocean and Walmart.
The January 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
There are many stocks that are targeted toward mature adults and seniors or that offer classical investing themes for those who are retired now or are within a decade of retiring.
A new addition to the Merrill Lynch US 1 list, plus four additional stocks that offer a fair degree of safety and solid dependable dividends. With the market volatility spiking, it makes sense to...
Merck released better-than-expected fourth-quarter financial results after the markets closed on Thursday.